Glenmark Pharma shares soar 3% on launching fixed-dose triple therapy for COPD

This comes after it launched the world's first nebulised, fixed-dose triple therapy for the treatment of chronic obstructive pulmonary disease, the drugmaker said in a regulatory filing.

The stock was trading 2.47% higher at ₹1,887.90 per equity share at around 2:33 pm.

The scrip has advanced about 2% over the last five days and more than 4% over the month. It has gained nearly 36% in the past six months and approximately 17% year-to-date.

While the share reached a 52-week high of ₹2,284.80 on July 11, 2025, it touched a year’s low of ₹1,275.50 apiece on February 28, 2025.

It launched Nebzmart GFB Smartules and Airz FB Smartules, which combine three proven medicines, including Glycopyrronium, Formoterol, and Budesonide, to reduce airway obstruction, inflammation, and improve lung function and symptom control, it said.

As a single, easy-to-use nebulised therapy, it minimises the burden of multiple medications, it added.

This marks a breakthrough as a new standard of care for COPD patients, especially those who struggle with using metered dose inhalers or dry powder inhalers, the Mumbai-based company stated.

Commenting on the development, Alok Malik, President & Business Head India Formulations, Glenmark Pharmaceuticals, said: “This milestone reinforces Glenmark's position as a front-runner in respiratory innovation and our commitment to making advanced, affordable, and accessible solutions for patients.”

In a clinical study conducted in India, the nebulised triple therapy demonstrated rapid improvement in lung function and better control of breathlessness (dyspnea) among patients, the drug maker added.

"This launch represents a significant advancement in the management of COPD and demonstrates our focus on strengthening global respiratory leadership," Glenmark Pharmaceuticals Global Head of Clinical Development Monika Tandon said.

Glenmark Pharma has a total market capitalisation of ₹53,333.13 crore, as of November 25, 2025, according to data on the NSE.